Literature DB >> 19286369

The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast.

E A Rakha1, M Aleskandarany, M E El-Sayed, R W Blamey, C W Elston, I O Ellis, A H S Lee.   

Abstract

UNLABELLED: The new gene expression molecular taxonomy of breast cancer places medullary carcinoma in the basal group. The basal group is considered to have a poor prognosis, but medullary carcinoma is considered to have a better prognosis than other grade 3 carcinomas. The prognostic significance of tumour associated inflammation, an important feature of medullary carcinomas, remains controversial. The aim of this study was to assess the prognostic importance of medullary histological type and inflammation in breast cancer. One thousand five hundred and ninety-seven patients who received no systemic adjuvant treatment and who had a median follow up of 9.5 years were studied.
RESULTS: Prominent inflammation was associated with high histological grade and with better survival [relative risk (RR) 0.57, 95% confidence intervals (CI) 0.44-0.74] on multivariate analysis. Typical and atypical medullary carcinomas (n=132) did not have significantly different survival and were grouped together. Medullary carcinoma did not have significantly different prognosis than grade 3 ductal carcinoma with prominent inflammation, but both had a better prognosis than grade 3 ductal carcinoma without prominent inflammation (P<0.0001 and P=0.03). These differences were independent of other prognostic factors. These results question the current separation of typical and atypical medullary carcinoma. Prominent inflammation is associated with a better prognosis, and may explain the better prognosis in medullary carcinoma compared with grade 3 ductal carcinoma without prominent inflammation. The good prognosis of medullary carcinoma emphasises the heterogeneity of basal-like breast carcinomas. Further studies are needed to investigate the difference in survival between medullary carcinoma and other forms of basal carcinomas and the role of inflammation in any such differences in behaviour.

Entities:  

Mesh:

Year:  2009        PMID: 19286369     DOI: 10.1016/j.ejca.2009.02.014

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  27 in total

1.  Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs.

Authors:  Lutfiye Demir; Seyran Yigit; Hulya Ellidokuz; Cigdem Erten; Isil Somali; Yuksel Kucukzeybek; Ahmet Alacacioglu; Suna Cokmert; Alper Can; Murat Akyol; Ahmet Dirican; Vedat Bayoglu; Aysegul Akder Sari; Mustafa Oktay Tarhan
Journal:  Clin Exp Metastasis       Date:  2013-07-09       Impact factor: 5.150

Review 2.  The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions.

Authors:  Felipe C Geyer; Fresia Pareja; Britta Weigelt; Emad Rakha; Ian O Ellis; Stuart J Schnitt; Jorge S Reis-Filho
Journal:  Am J Pathol       Date:  2017-07-20       Impact factor: 4.307

Review 3.  A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition.

Authors:  Hans-Peter Sinn; Hans Kreipe
Journal:  Breast Care (Basel)       Date:  2013-05       Impact factor: 2.860

4.  A methyl-deviator epigenotype of estrogen receptor-positive breast carcinoma is associated with malignant biology.

Authors:  J Keith Killian; Sven Bilke; Sean Davis; Robert L Walker; Erich Jaeger; M Scott Killian; Joshua J Waterfall; Marina Bibikova; Jian-Bing Fan; William I Smith; Paul S Meltzer
Journal:  Am J Pathol       Date:  2011-05-13       Impact factor: 4.307

5.  Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials.

Authors:  J Huober; S Gelber; A Goldhirsch; A S Coates; G Viale; C Öhlschlegel; K N Price; R D Gelber; M M Regan; B Thürlimann
Journal:  Ann Oncol       Date:  2012-06-14       Impact factor: 32.976

Review 6.  NO to breast: when, why and why not?

Authors:  Shehla Pervin; Gautam Chaudhuri; Rajan Singh
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 7.  Genomic analyses as a guide to target identification and preclinical testing of mouse models of breast cancer.

Authors:  Christina N Bennett; Jeffrey E Green
Journal:  Toxicol Pathol       Date:  2010-01-15       Impact factor: 1.902

8.  Clinicopathologic characteristics at diagnosis and the survival of patients with medullary breast carcinoma in China: a comparison with infiltrating ductal carcinoma-not otherwise specified.

Authors:  A-Yong Cao; Min He; Liang Huang; Zhi-Ming Shao; Gen-Hong Di
Journal:  World J Surg Oncol       Date:  2013-04-22       Impact factor: 2.754

9.  Immune aspects of the breast tumor microenvironment.

Authors:  Akhil Chawla; Gheath Alatrash; Yun Wu; Elizabeth A Mittendorf
Journal:  Breast Cancer Manag       Date:  2013-05-01

Review 10.  [Invasive breast cancer: the current WHO classification].

Authors:  A Lebeau; M Kriegsmann; E Burandt; H-P Sinn
Journal:  Pathologe       Date:  2014-02       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.